Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer

BACKGROUND: Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This study investigates benefits and harms of screening strategi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Natl Cancer Inst
Hlavní autoři: Heijnsdijk, Eveline A M, Gulati, Roman, Tsodikov, Alex, Lange, Jane M, Mariotto, Angela B, Vickers, Andrew J, Carlsson, Sigrid V, Etzioni, Ruth
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566340/
https://ncbi.nlm.nih.gov/pubmed/32067047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djaa001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky